Dasotraline: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Dasotraline''' is a [[ | {{Short description|Overview of the drug Dasotraline}} | ||
{{Drugbox | |||
| image = Dasotraline.svg | |||
| image_size = 200px | |||
| image_alt = Chemical structure of Dasotraline | |||
}} | |||
'''Dasotraline''' is a [[medication]] that was under development for the treatment of [[attention deficit hyperactivity disorder]] (ADHD) and [[binge eating disorder]]. It is a [[dopamine]] and [[norepinephrine reuptake inhibitor]] (DNRI), which means it works by increasing the levels of these neurotransmitters in the brain. | |||
==Pharmacology== | ==Pharmacology== | ||
Dasotraline is a | Dasotraline is classified as a [[dopamine reuptake inhibitor]] and a [[norepinephrine reuptake inhibitor]]. It has a long half-life, which allows for once-daily dosing. The drug's mechanism of action involves blocking the reuptake of dopamine and norepinephrine, thereby increasing their availability in the [[synaptic cleft]]. This action is thought to contribute to its therapeutic effects in ADHD and binge eating disorder. | ||
==Development== | |||
Dasotraline was developed by [[Sunovion Pharmaceuticals]]. It was investigated in clinical trials for the treatment of ADHD and binge eating disorder. However, as of the latest updates, the development of dasotraline for these indications has faced challenges, and its approval status remains uncertain. | |||
==Clinical Trials== | ==Clinical Trials== | ||
Clinical trials for dasotraline have shown mixed results. In studies for ADHD, dasotraline demonstrated efficacy in reducing symptoms compared to placebo. However, concerns about side effects and the overall benefit-risk profile have been raised. In trials for binge eating disorder, dasotraline showed promise in reducing binge eating episodes. | |||
==Side Effects== | |||
Common side effects of dasotraline include insomnia, decreased appetite, and dry mouth. Some patients may experience increased heart rate and blood pressure. As with other medications affecting neurotransmitter levels, there is a potential for more serious side effects, which necessitates careful monitoring by healthcare providers. | |||
==Regulatory Status== | ==Regulatory Status== | ||
The regulatory status of dasotraline has been complex. While it has shown potential in clinical trials, regulatory agencies have requested additional data to better understand its safety and efficacy profile. As a result, its approval for clinical use has been delayed. | |||
== | ==Related pages== | ||
* [[Attention deficit hyperactivity disorder]] | * [[Attention deficit hyperactivity disorder]] | ||
* [[Binge eating disorder]] | * [[Binge eating disorder]] | ||
* [[Dopamine reuptake inhibitor]] | |||
* [[Norepinephrine reuptake inhibitor]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category: | [[Category:Dopamine reuptake inhibitors]] | ||
[[Category: | [[Category:Norepinephrine reuptake inhibitors]] | ||
Revision as of 04:06, 13 February 2025
Overview of the drug Dasotraline
| Dasotraline | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Dasotraline is a medication that was under development for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder. It is a dopamine and norepinephrine reuptake inhibitor (DNRI), which means it works by increasing the levels of these neurotransmitters in the brain.
Pharmacology
Dasotraline is classified as a dopamine reuptake inhibitor and a norepinephrine reuptake inhibitor. It has a long half-life, which allows for once-daily dosing. The drug's mechanism of action involves blocking the reuptake of dopamine and norepinephrine, thereby increasing their availability in the synaptic cleft. This action is thought to contribute to its therapeutic effects in ADHD and binge eating disorder.
Development
Dasotraline was developed by Sunovion Pharmaceuticals. It was investigated in clinical trials for the treatment of ADHD and binge eating disorder. However, as of the latest updates, the development of dasotraline for these indications has faced challenges, and its approval status remains uncertain.
Clinical Trials
Clinical trials for dasotraline have shown mixed results. In studies for ADHD, dasotraline demonstrated efficacy in reducing symptoms compared to placebo. However, concerns about side effects and the overall benefit-risk profile have been raised. In trials for binge eating disorder, dasotraline showed promise in reducing binge eating episodes.
Side Effects
Common side effects of dasotraline include insomnia, decreased appetite, and dry mouth. Some patients may experience increased heart rate and blood pressure. As with other medications affecting neurotransmitter levels, there is a potential for more serious side effects, which necessitates careful monitoring by healthcare providers.
Regulatory Status
The regulatory status of dasotraline has been complex. While it has shown potential in clinical trials, regulatory agencies have requested additional data to better understand its safety and efficacy profile. As a result, its approval for clinical use has been delayed.
